

Outline of Initial Listing Issue

* As the Company decided on Mar. 5 not to proceed with a Secondary Distribution (Placement Underwritten and Purchased by Principal Underwriting Participants), the description relating to said secondary distribution has been deleted from the section “Public Offering / Secondary Distribution,” and the section “Original Share Offerors” has also been removed.

Company Name	J-Pharma Co.,Ltd.
Scheduled Listing Date	Mar. 25, 2026
Market Section	Growth Market
Current Listed Market	N/A
Name and Title of Representative	YOSHITAKE Masuhiro, President & CEO
Address of Main Office	1-10-11, HamamatsuCho, Minato-Ku Tokyo, 105-0013 Tel. +81-3-6432-4270
(Closest Point of Contact)	(Same as above)
Home Page	https://www.j-pharma.com/en/
Date of Incorporation	Dec. 26, 2005
Description of Business	Drug discovery and development targeting SLC transporters
Category of Industry / Code	Pharmaceutical / 520A(ISIN JP3387030004)
Authorized Total No. of Shares to be Issued	58,358,000 shares
No. of Issued Shares	14,589,610 shares (As of Feb. 19, 2026)
No. of Issued Shares (incl. treasury shares) at the Time of Listing	17,829,610 shares (Note 1) The number includes newly issued shares issued through the public offering. (Note 2) The number could increase as a result of the exercise of share options, etc.
Capital	JPY 682,700 thousand (As of Feb. 19, 2026)
No. of Shares per Share Unit	100 shares
Business Year	From Apr. 1 to Mar. 31 of the following year
General Shareholders Meeting	Within 3 months after the end of the business year
Record Date	Mar. 31
Record Date of Surplus Dividend	Sep. 30 and Mar. 31
Transfer Agent	Sumitomo Mitsui Trust Bank, Limited
Auditor	GINGA AUDIT CORPORATION
Managing Trading Participant	SBI SECURITIES Co.,Ltd.

(Reference Translation)

<Overview of Public Offering and Secondary Distribution >

Public Offering / Secondary Distribution	Public Offering (Newly Issued Shares) Secondary Distribution (Placement by over-allotment scheme)	3,240,000 shares 486,000 shares
Offering Price Determination Method	Book-building method	
Provisional Conditions Determination Date	Mar. 5, 2026	
Book-building Period	Mar. 6, 2026 to Mar. 12, 2026	
Offering Price Determination Date	Mar. 13, 2026	
Subscription Period	Mar. 16, 2026 to Mar. 19, 2026	
Payment Date	Mar. 24, 2026	
Settlement Date	Mar. 25, 2026	
Principal Underwriting Participants	SBI SECURITIES Co.,Ltd. Daiwa Securities Co. Ltd. Tokai Tokyo Securities Co., Ltd. TOYO SECURITIES CO.,LTD. MATSUI SECURITIES CO.,LTD. Monex, Inc. Rakuten Securities, Inc.	

- (Note 1) Tokyo Stock Exchange, Inc. approves new listings based on the results of the examination by Japan Exchange Regulation.
- (Note 2) The “Initial Listing Application Securities Report (Part I)” (only in Japanese) of the company is available on the JPX official website. Please refer to such release for details.
- (Note 3) Buy and sell market orders for this issue are prohibited in transactions carried out up to and including the initial price determination date.